Mendus AB (publ)

Thanks and welcome everybody to the Q4 and year-end webcast and business update of Mendes. My name is Eric Menting, CEO. I'm together with our CFO, Lotte Verm. As a summary of the main events of Q4, very importantly, we presented a survival update of our advanced two trial in AML at the American Society of Hematology Conference at the end of last year, which demonstrated continued long-term survival in the majority of patients. We also presented that as additional abstracts, which support the broader positioning of vidiDen cell in acute myeloid leukemia and also adjacent diseases such as chronic myeloid leukemia, which may support the further broadening of the addressable patient population with the lead product vidiDen cell. The positive top line data from the LSN phase 1 trial that we presented in December indicates that we have a positive start of treating ovarian cancer patients with VD-DenCell and that we can observe immune responses after VD-DenCell administration against antigens that have previously been shown to be relevant for ovarian cancer, indicating that we are triggering tumor-directed immune responses. Safety was very good, and we're now awaiting longer-term survival data in Q4 of this year to see how the VidaDen cell product could be potentially developed in ovarian cancer. For the intratumoral primer that we are developing, elixir-den-cel, we showed that it combines well with the immune checkpoint inhibitor Avalimab, and we presented those data at the Society for Immunotherapy of Cancer conference in the end of last year. But unfortunately, the clinical trial that we had anticipated to take place at Institut Bergogne and a number of other larger French hospitals came to an end because the overall trial, third-party funding was stopped and we were part of this trial to study illicit end-cell and soft tissue sarcomas. With the trial stopping, that's unfortunately no longer an opportunity. And we will look to potentially partner in this program to take it forward in the clinic. Importantly, end of last year, we also received feedback from the FDA and EMA, so the regulatory agencies in the US and Europe, on our registration trial preparations for VD-DenCell. And what that indicated is that we're on the right track. It means we are preparing for a trial that they consider appropriate, but also that the steps we are taking towards that late stage trial, including the setting up of large scale manufacturing, is in accordance with their expectations. And finally, the large scale manufacturing alliance that we have with North X biologics is on track. And that's an important step to take towards pivotal stage readiness. Now shifting to the numbers of Q4, I'll hand over the word to Lotte.

Yeah. Hello everyone. And I will not talk so much about this. You can say what, but what I would like to highlight is the difference between the the costs in the company and the cash burn. As you can see in the report, the costs for the year has been around 136 million Swedish crown, but the cash flow for the year is only 20 million. And that's because of the warrants, which get in some extra cash in the beginning of the year. But also in the Q4, the cash position changed only with eight millions from the end of Q3. And that's because we've got some grants and also some interest on the bank accounts. And grants is very important for us because that's how we have fundings for most of our preclinical work in the company. And the cash runway now will take us until the beginning of 2026. Thanks.

So as a pipeline overview, we are currently preparing for a registration trial with our lead product, vidiDenCell in AML. We are still monitoring the ongoing phase two data from the advanced two trial, and we are expanding the clinical development of vidiDenCell in blood-borne tumors with the first trial ongoing, which is the CADENCE trial together with the oscillation leukemia lymphoma group. And as I indicated, we are also exploring additional indications in the blood-borne tumor space. And then we have the solid tumor programs, which is the earlier stage allicin trial in ovarian cancer, which is still to be confirmed in the sense of the next survival readout. And we have the Elixir Densel program, which we believe would make an interesting partnering opportunity for potential pharmaceutical or other biotechnological companies. So shifting to the main program, the main need for the treatment of AML currently is called maintenance therapy. And the reason is that AML or curamide or leukemia is a very aggressive blood-borne tumor that affects around 45,000 people annually in Europe and the US only, and around 145,000 people globally. And it can only be treated with intensive chemotherapy and immediate chemotherapy to reduce the tumor burden the big problem is the recurrence of the tumor and the only way to prevent it currently is a bone marrow or hematopoietic stem cell transplant but it's unavailable for the majority of patients and also a lot of patients already relapse before they are even in a position to undergo such a procedure so the need for maintenance therapies that are able to prolong disease-free and overall survival is huge And that particularly relates to a phenomenon called measurable residual disease, or MRD, which is present in the majority of patients after chemotherapy and is a critical factor in predicting relapse. So there's an increased association of relapse with MRD-positive patients. VD-DEN cell addresses this medical need. So it's a maintenance immunotherapy designed to improve relapse-free and overall survival in AML. The way it works is that after the initial treatment, when the disease burden is low, we can administer VitaDenCell through intradermal injections, so injections into the skin. It stimulates the immune system with the aim to reduce the recurrence of the AML. In the ADVANCE-II trial, as a reminder, we have administered six vaccinations, four biweekly vaccinations, followed by two boosters. The trial was conducted in 10 hospitals across Europe. The active study phase was completed, but we're now in long-term follow-up, and the updated survival data of that long-term follow-up was presented at ASH in December 24. This was the data we presented, and as you can see, there is a continued long-term survival in the majority of patients, and that's both relapse-free and overall survival of patients that have been treated with VD-Denso. All of these patients were MRD-positive at study entry, And as you will see, in the first year, a lot of patients relapse and pass away. It was six patients in this case. But then the intriguing part is that the majority of patients stayed alive and then also stayed alive over a long period of time. What we could also show and presented at ASH is that the prolonged survival is associated with the immune responses that are stimulated by VDDenCell treatment. And what you see in this graph is the difference between patients that had a sustained immune response, so over time, multiple immune responses following VDDenCell administration, and they are doing very well and significantly better than the patients without such a sustained vaccine-induced response. But what we saw more than this, we also saw that B cells play a role, so the cells that produce antibodies. And we also realized that some patients had relatively high levels of suppressor cells called LEK3 positive T cells, even before the start of treatment. And that also was predictive of the outcome of the treatment. so the treatment itself leads to an increase in b cells and an increase in t cell responses as you can see in this graph but also it led to a reduction of these inhibitory t cells and also at baseline so before we started treating patients we can already see that the patients that have a poor immune profile are also the patients that relapse relatively quickly so the other way around all the patients that had a good immune response we're all long-term survivors. And this is a very clear pattern that we can link to the mode of action of VD-DenCell. And combined with the survival data, this is proof of concept that VD-DenCell acts as an active immunotherapy against residual disease in AML. And that puts us in a unique position to move this program forward. So we've decided to proceed towards a phase three trial or registration trial and to make sure that the program is ready. So on the one hand, that means we are designing a trial and we keep a close contact with the regulators to make sure that the trial we design would be a trial that would be sufficient for product registration. But also in parallel, we are setting up the large scale manufacturing of Ididencel. And why is that relevant? It is because you want to have the final production process for your product ready and in place and also with the material coming out of that process before you start a potential registration trial. You don't want to change the manufacturing protocol during the trial and that's why this pivotal stage readiness is so much dependent on the manufacturing. with the feedback that we got from EMA and FDA, we got more comfortable with the fact that we are on the right track. And that doesn't mean only for the trial, but also for the manufacturing and also for the whole dossier that we have around VDDN cell, the regulatory dossier, but also the way we look at comparability, for example, of the product that we had from our old manufacturing process and now the product that we will get out of the new large scale manufacturing process. So it means that we are on track in preparing for pivotal stage readiness. Why is this important? First and foremost, we want to get this product on the market and that will require, of course, additional means it can mean a partnership, additional funding, or a combination of both. Uh, but one way or the other, the program has to reach this stage because that makes it the product. And I can't emphasize that enough. This pivotal stage readiness is really a crucial milestone in the development of the product. And if we take that hurdle and we are well on the way, I think we have a very attractive program to take forward either by ourselves or in the partnership. The broader AML maintenance landscape looks like this. So we are currently treating patients that come out of high-dose or high-intensity chemotherapy. And currently, the only approved drug for AML maintenance in the patient population is a drug called oral azacitidine. And this is the current positioning. So the trial that we showed, the ADVANCE2 trial, is a single agent trial. It's a monotherapy trial. But as a next step, we want to combine with standard of care. And then you also have additional maintenance populations in the post transplant setting. So patients with transplants also have high levels of relapse. Actually, relapse is the most dominant factor for transplant failure. So that is a patient population that could benefit from pre-dental treatment. And then there's also the chemo unfit patients, patients that are not able to undergo the high-intensity chemotherapy, who are today treated by a combination of azacytidine with venetoclax. So these are two backbone drugs in the treatment of AML. And when you combine them, we're seeing higher complete remission rates in patients that were previously deemed untreatable or at least not treatable with chemotherapy. So that's a big shift in the AML field. It also means that more patients achieve complete remissions with this combination, and they're also eligible for maintenance therapy. The big challenge is that azacitidine as a backbone drug is relatively safe, but not very effective in the treatment of AML. The other way around, the venetoclax is rather toxic and very effective, but then also very difficult to handle as a maintenance drug. And this is where we believe we have a unique positioning of EDDent cell in the broader AML landscape. But also there's additional opportunities in other blood-borne tumors. So as step one, we will combine with oral azacitidine. The graph on the right shows the current drug oral azacitidine. And this was data from the registration trial. So the phase three trial in MRD positive patients. And what you will see is that you see a very past relapse, so this is relapse-free survival, and that that relapse is slowed down by the azacitidin. That in itself is a reason to combine with azacitidin, but also there is a medical scientific rationale to combine VDN cell with oral azacitidin. And the reason is that the azacitidin has been shown in other trials to work very well in combination with immunotherapy approaches. And the main reason being that it increases the immunogenicity of cancer cells. combined and also based on our own preclinical assessments, we believe that this combination will be beneficial for AML patients. The first trial that we have launched in the expansion of the VDN cell clinical development is a trial run by ALLG, the Oscillation Leukemia and Lymphoma Group. The setup of the trial is initially 40 patients to assess safety and tolerability, and then we can expand to a larger trial, up to 100 patients extra to look into the feasibility. This trial is for both MRD positive and MRD negative patients, and it exposes also the product to a much wider group of hospitals because there's a lot of hospitals associated with ALLG, and we are currently opening up multiple hospitals, or ALLG, I should say, is opening up multiple hospitals throughout Australia to support this trial. Then we have also looked into the additional maintenance opportunities, and this is just to indicate that we are preparing for additional trials to potentially capture and broaden the addressable patient population in AML and potentially also adjacent diseases such as chronic myeloid leukemia, which is similar in terms of immunological profile, but it's a different kind of disease. It's slower disease than AML, much larger patient population, and There's a high need in chronic myeloid leukemia to provide patients with solutions to don't have to take lifelong drugs. And immunotherapy could bring that solution. But of course, we need to test whether VDDen cell could be a potentially interesting drug to try and achieve those treatment-free remissions. What we have presented at ASH were supportive data for the AZA plus venetoclax combination that I mentioned earlier, but also supportive data to study VDN cell in chronic myeloid leukemia. Then if we look at the other programs, the ovarian cancer program, as I mentioned, has shown promising initial data. So not only have we seen tumor-directed responses in the majority of patients, but also most of the patients, eight out of 12 with vaccine-induced responses had stable disease at week 22. So there seems to be an association between these responses and the disease progression, but we have to be very careful at this point in time to make stronger statements. The next follow-up will be in the fourth quarter of this year when we will have two-year follow-up data from all the patients treated. Then for Elixir Densel, it's a program that we have put a lot of effort in. It's been in the clinic extensively. We've focused on making the manufacturing more robust and we were ready to go into a trial together with Institut Bergogne. But since the trial that we were part of was stopped, we have to reconsider our strategy and we have decided to look for potential partners. The main reason being that we have to focus on the lead program where we see the strongest data currently, but also we believe that in solid tumors, there will be more and more combination strategies to treat difficult to treat tumors. And we want to be part of that, but ideally in the form of a partnership. So to summarize, the updated survival data from the ADVANCE-II trial at ASH demonstrate and continue to demonstrate durable survival benefit of AML patients treated with 3D Densel. Preparations for registration trial are ongoing, and they are now also endorsed by the feedback we received end of last year by EMA and FDA. We have established the large scale manufacturing alliance with Northex Biologics and are also on track for the major milestone that we want to achieve of GMP readiness. So the readiness to make clinical grade material in the second half of next year. And that will also be an important milestone for the pivotal stage readiness of VD-DenCell as a program. We are expanding the clinical development of VD-DenCell with the CADENS trial or AMLM22 CADENS trial in combination with oral azacitidine. And we are also preparing for additional trial opportunities to broaden the addressable patient population in AML and adjacent diseases. The Elixir Densel program is still an opportunity, but we will look to partner that program. And the Allison Phase 1 trial in ovarian cancer is an earlier stage program, which is expected to deliver the next readout based on two-year follow-up in 2025 Q4, after which we can make clearer statements on what we're going to do with that program. So with that, I would like to thank you on behalf of the management team and the board and open for Q&A.